Cytokinetics Inc is committed to improving the lives of patients by developing innovative therapies in the field of muscle biology. The company's core values include integrity, collaboration, and dedication to scientific excellence. Cytokinetics is driven by a corporate philosophy that emphasizes scientific rigor, patient-centricity, and a strong commitment to advancing medical knowledge. By working closely with key stakeholders, including healthcare professionals and patients, Cytokinetics aims to address unmet medical needs and make a positive impact on global healthcare. With its cutting-edge research and development efforts, Cytokinetics Inc strives to bring new treatment options to patients suffering from serious diseases and disorders affecting muscle function.

Cytokinetics Inc is primarily present in the United States.

Cytokinetics Inc has achieved significant milestones in its journey. One notable achievement is the development of omecamtiv mecarbil, a potential treatment for heart failure. The company has successfully completed various clinical trials, demonstrating promising results in improving cardiac function. Additionally, Cytokinetics Inc has advanced its research in muscle biology and therapeutics, leading to collaborations with renowned pharmaceutical companies and medical institutions. Furthermore, the company's continuous dedication to innovation and scientific excellence has resulted in numerous patents and publications. These milestones highlight Cytokinetics Inc's commitment to delivering innovative solutions and advancing the field of cardiac and skeletal muscle disorders.

Cytokinetics Inc is a renowned biopharmaceutical company specializing in the discovery and development of muscle biology-focused therapies. Established in 1997, the company has emerged as a leading player in the field, harnessing the power of sarcomere-directed drug candidates. Cytokinetics' innovative research and development aim to address diseases associated with muscle impairment and dysfunction. With a strong focus on cardiovascular and neuromuscular diseases, Cytokinetics Inc continues to progress its pipeline of potential treatments with the goal of improving patients' lives. Their commitment to scientific advancement and clinical collaboration places Cytokinetics Inc at the forefront of efforts to tackle serious medical conditions.

The main competitors of Cytokinetics Inc in the market include pharmaceutical companies such as Amgen, Biogen, and Novartis. These companies also specialize in the development of cutting-edge therapies and drugs for various medical conditions. However, Cytokinetics Inc distinguishes itself through its novel approach to drug discovery, focusing on the field of muscle biology and developing potential treatments for diseases related to muscle dysfunction. With its innovative research and development strategies, Cytokinetics Inc aims to make significant contributions to the pharmaceutical industry and provide solutions that address unmet medical needs.

Cytokinetics Inc is primarily active in the pharmaceutical and biotechnology industries.

The business model of Cytokinetics Inc is focused on the discovery and development of novel muscle activators as potential treatments for debilitating diseases. Cytokinetics utilizes its expertise in muscle biology to develop small molecule drug candidates that target muscle function and address diseases such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and hypertrophic cardiomyopathy (HCM). By designing innovative therapies that aim to improve muscle performance, Cytokinetics aims to provide hope for patients suffering from these conditions and enhance their overall quality of life through its scientific research and drug development efforts.

P/E odnos Cytokinetics iznosi -8,39.

KUV kompanije Cytokinetics iznosi 697,62.

AlleAktien kvalitativni skor za Cytokinetics je 4/10.

očekivana Cytokinetics promet je 7,48 mil. USD.

Dobit očekivana Cytokinetics je -622,23 mil. USD.

Cytokinetics Inc. is a biopharmaceutical company based in South San Francisco, California. The company specializes in the development of novel therapeutics for severe, chronic diseases of the heart muscle and skeletal muscle. It utilizes expertise in cell biology, medical technology, and drug development to create precision medicine therapies tailored to clinical needs. The company has two main divisions: Cardiovascular and Neuromuscular. The Cardiovascular division focuses on developing therapeutics for diseases of the heart muscle and blood vessels. This includes heart muscle diseases such as heart failure and arrhythmias, as well as vascular diseases such as peripheral arterial disease and pulmonary arterial hypertension. The Neuromuscular division specializes in developing therapeutics for diseases of the skeletal muscle. This includes neuromuscular diseases such as spinal muscular atrophy, amyotrophic lateral sclerosis, and Duchenne muscular dystrophy. Cytokinetics develops its therapeutics using an innovative class of drugs known as myosin activators. A myosin activator is a substance that activates the enzyme myosin, which is responsible for muscle contraction. By activating myosin, the muscle can work better and more effectively. One of Cytokinetics' key products is the investigational drug Omecamtiv Mercabil. It is an oral myosin activator for the treatment of heart failure. Omecamtiv's mechanism is aimed at increasing the contractile force of the heart muscle to improve blood flow and pumping. The continuous research and development of drugs like Omecamtiv Mercabil have the potential to usher in a new era of treatment for cardiovascular diseases. Cytokinetics also has a partnership with Astellas Pharma Inc. for the joint development of Reldesemtiv for spinal muscular atrophy, CK-274 for hypertrophic cardiomyopathy, and other neuromuscular indications. Collaborating with partners increases the likelihood of rapid and successful drug development and accelerates market introduction. Cytokinetics' business model is based on partnerships with other companies to accelerate the research and development of therapeutics for severe, chronic diseases of the heart muscle and skeletal muscle. By leveraging innovative technologies and platforms, and integrating data, human experience, and scientific intelligence, Cytokinetics brings novel medicines to market that could improve the quality of life for millions of patients worldwide.

Cytokinetics isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Cytokinetics trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Cytokinetics je US23282W6057.

WKN od Cytokinetics je A1W1KK.

Oznaka za praćenje akcija kompanije Cytokinetics je CYTK.

U poslednjih 12 meseci, Cytokinetics je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Cytokinetics će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Cytokinetics trenutno iznosi .

Cytokinetics isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Cytokinetics je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Cytokinetics se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Cytokinetics od 9. 9. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 9. 9. 2024..

Isplata poslednje dividende izvršena je 9. 9. 2024..

U godini 2023 kompanija Cytokinetics je isplatila 0 USD kao dividende.

Dividende od Cytokinetics se isplaćuju u USD.